Andrey Ugolkov, MD, PhD

Dr. Andrey Ugolkov brings more than 25 years of clinical and translational oncology experience. Dr. Ugolkov is a physician-scientist with broad experience in clinical drug development, immuno-oncology, pathology, and biomarker development. He contributed to numerous drug development programs from early discovery, preclinical to clinical development, IND submissions, and Phase 1/2 clinical studies.

After graduation from medical school and completing his medical residency, Dr. Ugolkov joined the Division of Surgical Oncology, Cancer Research Institute Hospital, Kanazawa University, Japan. He received a Ph.D. in surgical oncology and pathology from Kanazawa University. Prior to joining Actuate Therapeutics, Dr. Ugolkov served as the Head of Translational Medicine at Curis, Inc. where he supported clinical development of novel immune checkpoint inhibitor CI-8993 and small molecule inhibitor of IRAK4/FLT3 CA-4948 for the treatment of solid tumors and hematological malignancies. Dr. Ugolkov served as a Director of Translational Modeling at Tempus between 2016 and 2019.

Prior to joining Tempus, Dr. Ugolkov was a research faculty member at the Division of Hematology and Oncology, Northwestern University. He held roles of increasing responsibility in discovery and development of novel oncology drugs (small molecule inhibitors, nanoparticles, therapeutic Ab) at the Center for Developmental Therapeutics, Northwestern University. Dr. Ugolkov was one of the scientific pioneers that discovered GSK-3beta as a therapeutic target in human cancer and helped with the discovery and development of best-in-class GSK-3 inhibitor elraglusib (9-ING-41). Dr. Ugolkov is a co-inventor on a number of patents and the co-author of more than 50 peer-reviewed publications and book chapters.